Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.49Last Year’s EPS
-0.36Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -13.62%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
NovoCure's earnings call reflects strong overall performance and significant achievements, particularly in expanding indications and clinical trial successes. However, challenges with reimbursement, increased operating expenses, and potential gross margin headwinds indicate areas of concern that need to be addressed.Company Guidance
In the NovoCure Fourth Quarter 2024 Earnings Conference Call, the company detailed significant progress and provided guidance for 2025. Key achievements for 2024 included generating $605 million in net revenue and increasing the global active patient count to over 4,000, with growth driven by strong performance in markets like France, Germany, and Japan. The company also highlighted its successful expansion beyond glioblastoma (GBM) to include FDA-approved treatments for non-small cell lung cancer, brain metastases from non-small cell lung cancer, and locally advanced pancreatic cancer. NovoCure's strategic focus for 2025 involves further growth in these new indications, with expectations of substantial revenue contributions from the lung cancer launch by 2026. Despite a net loss of $169 million for the year, the company reported an adjusted EBITDA of $1 million and maintained a strong cash position of $960 million, aiming for future profitability as they expand their market reach.Revenue Growth and Financial Performance
NovoCure generated $605 million in net revenue for 2024, a 19% increase year-over-year, with a 21% increase in Q4 2024 compared to the same period in 2023. The company achieved a gross margin of 77% for the year, up from 75% in 2023, driven by improved US approval rates.
Expansion into New Indications
Received FDA approval for the treatment of second-line non-small cell lung cancer with Optune Lua. Achieved successful Phase 3 readouts for METIS (brain mets from non-small cell lung cancer) and PANOVA-3 (locally advanced pancreatic cancer), marking a pivotal expansion from a single indication to a multi-indication platform.
Clinical Trial Success
METIS trial met its primary endpoint with patients exhibiting 21.9 months median time to intracranial progression. PANOVA-3 trial demonstrated a median overall survival of 16.2 months, showing significant benefits in difficult-to-treat populations.
Product Development Milestones
Approved HFE arrays in the US and Japan, which are thinner, lighter, and more flexible, aiming to improve patient usage and expand market reach.
---
NVCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $21.96 | $19.23 | -12.43% |
| Oct 30, 2024 | $16.89 | $16.99 | +0.59% |
| Jul 25, 2024 | $18.79 | $18.65 | -0.75% |
| May 02, 2024 | $12.74 | $14.19 | +11.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NovoCure Ltd (NVCR) report earnings?
NovoCure Ltd (NVCR) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is NovoCure Ltd (NVCR) earnings time?
NovoCure Ltd (NVCR) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVCR EPS forecast?
NVCR EPS forecast for the fiscal quarter 2025 (Q1) is -0.49.
---